PLIANT THERAPEUTICS INC
For the period ended Dec 31, 2024. Filed Mar 3, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 3, 2025
PLRX$0.80-1.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
(In thousands)
| Year Ended December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Cash flows from operating activities | |||
| Net loss | $(210,304) | $(161,336) | $(123,321) |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Depreciation expense | 2,125 | 1,841 | 1,823 |
| Stock-based compensation expense | 37,626 | 44,483 | 22,598 |
| Non-cash operating lease expense | 3,451 | 2,390 | 1,858 |
| Amortization (accretion) on short-term investments and debt | 2,510 | (4,990) | (1,806) |
| Changes in operating assets and liabilities: | |||
| Accounts receivable | — | 1,983 | 15 |
| Prepaid expenses and other current assets | 4,717 | (3,735) | (294) |
| Other non-current assets | (43) | — | 201 |
| Accounts payable | 1,428 | 2,969 | (1,351) |
| Accrued liabilities | 3,807 | 2,781 | 7,904 |
| Operating lease liabilities | (820) | (2,747) | (2,258) |
| Net cash used in operating activities | (155,503) | (116,361) | (94,631) |
| Cash flows from investing activities | |||
| Purchase of short-term investments | (211,285) | (583,069) | (325,716) |
| Maturity of short-term investments | 355,473 | 456,978 | 177,272 |
| Purchase of property and equipment | (3,848) | (921) | (1,760) |
| Net cash provided by (used in) investing activities | 140,340 | (127,012) | (150,204) |
| Cash flows from financing activities | |||
| Proceeds from sale of common stock in a public offering | — | 270,251 | 216,201 |
| Proceeds from issuances of common stock under benefit plans | 3,207 | 5,001 | 1,360 |
| Payment of offering costs | — | (847) | (557) |
| Proceeds from term loan, net of issuance costs | 19,910 | — | 9,850 |
| Net cash provided by financing activities | 23,117 | 274,405 | 226,854 |
| Net increase (decrease) in cash and cash equivalents | 7,954 | 31,032 | (17,981) |
| Cash, cash equivalents and restricted cash at beginning of period | 64,716 | 33,684 | 51,665 |
| Cash, cash equivalents and restricted cash at end of period | $72,670 | $64,716 | $33,684 |
| Supplemental disclosures of cash flow information: | |||
| Cash paid for interest | $2,620 | $1,149 | $615 |
| Reconciliation of cash, cash equivalents, and restricted cash reported in the balance sheets | |||
| Cash and cash equivalents | $71,188 | $63,234 | $33,684 |
| Restricted cash | 1,482 | 1,482 | — |
| Total cash, cash equivalents, and restricted cash shown in the statements of cash flows | $72,670 | $64,716 | $33,684 |
| Supplemental disclosures of noncash investing and financing activities: | |||
| Net unrealized (loss) gain on short-term investments | $(24) | $2,303 | $(1,757) |
| Purchase of property and equipment in accounts payable | $236 | $— | $— |
| Reclassification of restricted stock awards from liabilities to common stock upon vesting | $— | $— | $2 |
| Supplemental disclosures of cash flow information related to leases: | |||
| Cash paid for operating lease liabilities in operating cash flows | $4,698 | $3,846 | $2,657 |
| Right-of-use assets obtained in exchange for new operating lease liabilities | $29,779 | $— | $950 |
| Decrease in right-of -use assets and liabilities from lease modifications | $— | $1,821 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.